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Abstract
The Aspergillus ribonuclease a-sarcin is toxic to intact mammalian cells but the mechanism by which it enters the cells
to reach its ribosomal RNA substrate is unclear. Here we have compared the cytotoxicity of a-sarcin to that of ricin,
another catalytic toxin that targets the same rRNA sequence but whose mechanism of cell entry is better understood. Intact
ricin binds to cell surface components and enters the cells by receptor-mediated endocytosis, whereas the catalytic
 .polypeptide of ricin the A chain or RTA which, like a-sarcin, is unable to bind to surface components directly and enters
cells by fluid phase uptake. Recombinant a-sarcin was produced in Escherichia coli and purified to homogeneity. The
protein was soluble, stable and its ability to inhibit in vitro protein synthesis was indistinguishable from that of native
a-sarcin. Further, recombinant a-sarcin had the same in vitro protein synthesis inhibition activity as ricin A chain. The
cytotoxicity of a-sarcin and ricin A chain to HeLa cells was also the same. The cytotoxicity of a-sarcin was due to its
RNAase activity rather than to specific membrane effects at the cell surface, since a mutant containing a single substitution
at a putative key catalytic residue had reduced ribonuclease activity and an equivalent reduction in cytotoxicity. One
interpretation of the data is that a-sarcin enters mammalian cells in the same way as free ricin A chain. q 1997 Elsevier
Science B.V.
Keywords: a-Sarcin; Ribotoxin; Cytotoxicity; Cell entry
1. Introduction
 .alpha-Sarcin a-sarcin is a member of the As-
pergillus ribotoxin family, a group of highly specific
ribonucleases that cleave a single phosphodiester bond
within a highly conserved loop structure present in
Abbreviations: RTA, ricin toxin A chain; RTB, ricin toxin B
chain; TKM buffer, 25 mM TrisPHCl, pH 7.6, 25 mM KClP5
mM MgCl2; BMV, brome mosaic virus; DMEM, Dulbecco’s
Modified Eagle’s Medium.
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w x28S ribosomal RNA 1 . The a-sarcin cleavage site
lies between a guanosine and adenosine residue in the
sequence AGUACGAGyAGGAAG. This univer-
sally-conserved rRNA sequence, sometimes referred
w xto as the ‘a-sarcin loop’ 2 , plays a key functional
role during protein synthesis as the site at which
w xelongation factors EF-1 and EF-2 bind 3,4 . This
important region of rRNA is also the target for other
protein toxins, such as the ricin toxin family of
w xribosome-inactivating proteins from plants 5 and the
w xShiga toxin family from bacteria 6 , although these
toxins are not ribonucleases but N-glycosidases that
remove the adenine residue immediately upstream of
w xthe G-A bond cleaved by a-sarcin 7,8 .
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The Aspergillus ribotoxins, including a-sarcin,
w xare toxic to intact mammalian cells 9 . Assuming
that this toxicity results from the catalytic action of
a-sarcin on rRNA, then this protein must be able to
cross a membrane in order to reach its ribosomal
substrate in the cytosol. Which membrane is tra-
versed and the mechanism by which this is achieved
is unclear at present. a-Sarcin has been reported to
effectively inhibit in vivo protein synthesis in several
w xtumour cell lines 9,10 and in virally-infected cells
w x11,12 . Studies using model membranes indicate that
a-sarcin interacts with acidic phospholipids promot-
w xing membrane aggregation and fusion 13,14 . It has
been suggested that these observations are significant
w xin relation to the cell entry mechanism 15 . How-
ever, HeLa cells were relatively insensitive to a-
sarcin but became more sensitive after treatment with
phospholipase C which permeabilised the cells to
allow entry of the toxin or other macromolecules
w x16 , indicating that the toxin could not readily cross
the plasma membrane.
In the present study we have compared the cell
entry characteristics of a-sarcin, measured as the
ability of externally added toxin to inhibit protein
synthesis in intact cells, with those of intact ricin or
 .free ricin A chain RTA . Ricin enters mammalian
cells by endocytosis and kills them by catalytically-
modifying the same 28S rRNA loop targeted by
w xa-sarcin 6 . RTA, which in common with a-sarcin
w xcan interact with model membranes 17,18 , does not
directly cross the plasma membrane but rather enters
cells by fluid phase uptake before subsequently fol-
lowing the same intracellular transport pathway as
w xthe endocytosed ricin holotoxin 19 . a-Sarcin and
RTA are shown to have very similar in vitro transla-
tion inhibition and cytotoxicity profiles, suggesting
that the mechanism of cell entry may also be similar
for these two protein toxins.
2. Methods
2.1. a-Sarcin expression
a-Sarcin was expressed in E. coli TG2 cells using
the secretion vector pIN.ompA2.preAS. This expres-
sion vector, kindly supplied by Dr. N. Ulbrich, en-
codes the OmpA N-terminal signal sequence fol-
lowed by mature a-sarcin. The a-sarcin insert was
w xchemically synthesised as described 20 using the
preferred E. coli codons. Transformed E. coli TG2
cells were grown in defined M9 medium at 378C to
an OD of 0.5 to 0.6. Expression was induced by600
the addition of IPTG to a final concentration of 0.5
mM, and the cells were shaken for a further 3 h at
378C. After harvesting, the cells were resuspended in
100 mM TrisPHCl, pH 9.0, 10 mM EDTA, and then
disrupted by sonication. Cell debris was removed by
centrifugation at 20 000 rpm for 15 min at 48C.
2.2. Purification of ra-sarcin
Ammonium sulfate was added to the homogenate
to 70% saturation. After centrifugation the pellet,
which contained the bulk of the endogenous bacterial
proteins, was discarded. The supernatant, by now
highly enriched for ra-sarcin, was loaded onto a
1.6=40 cm CM-Sepharose column. The remaining
E. coli proteins, which did not bind to the column,
were removed by washing with 100 mM TrisPHCl,
pH 9.0, 10 mM EDTA, before ra-sarcin was eluted
as a single protein peak using a linear gradient of
 .NaCl 0 to 750 mM in the same buffer. Native
a-sarcin isolated from Aspergillus giganteus was
kindly provided by Dr. N. Ulbrich. The concentration
of purified a-sarcin wdetermined from the A value;280
a calibration curve prepared for native a-sarcin giv-
ing a molar extinction coefficient at 280 nm of
2.46P104.
2.3. Assaying ra-sarcin for biological acti˝ity
2.3.1. Specific rRNA clea˝age
Various concentrations of ra-sarcin were incu-
bated for 30 min at 308C with 30 mg of rabbit
reticulocyte ribosomes non-nuclease treated, from
.Promega in 20 ml of 25 mM TrisPHCl, pH 7.6, 25
 .mM KCl and 5 mM MgCl TKM buffer . Riboso-2
mal RNA was extracted and fractionated by for-
mamide agarose gel electrophoresis as described pre-
w xviously 21 .
2.3.2. Protein synthesis inhibition
Various concentrations of ra-sarcin or RTA where
.appropriate were added to in vitro assays in which
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 .brome mosaic virus BMV mRNA was translated in
 .nuclease-treated rabbit reticulocyte lysates Promega
containing unlabelled amino acids with the exception
w35 x w xof S methionine 21 . Total radiolabelled protein
synthesised was expressed as a percentage of the
amount synthesised in control translations without
added toxin.
2.4. Cytotoxicity assays
HeLa cells were plated in 96 well flat bottom
tissue culture plates at a density of 1.5 P 104
cellsrwell in 100 ml of Dulbecco’s modified Eagle’s
 .medium DMEM containing 5% foetal calf serum, 2
mM glutamine, 50 Urml penicillin and 50 Urml
streptomycin. After overnight incubation at 378C in a
CO incubator, the DMEM was shaken off the cells2
and various concentrations of ra-sarcin or other toxin
in 100 ml of fresh DMEM were added to the cells
 .and incubated at 378C overnight 16 h . The cells
were washed in PBS, and protein synthesis was
w35 xmeasured by the addition of 1 mCi of S methionine
in 50 ml of PBS and incubation at 378C for 2 h.
Radiolabelled proteins were precipitated by three
washes with 5% trichloroacetic acid and, after three
further washes with PBS, were released with 50 ml
of 0.5 M NaOH and the incorporated radioactivity
was determined by scintillation counting.
2.5. Preparation of ribosomes
1 ml of non-nuclease treated rabbit reticulocyte
lysate was layered over 1 ml of 1 M RNase-free
sucrose solution in TKM buffer contained in a poly-
carbonate ultracentrifuge tube. After centrifugation at
100 000=g for 40 min at 48C in a Beckman TL-100
centrifuge, the lysate and sucrose solution was care-
fully removed. The ribosome pellet was washed three
times by resuspension in 1 ml of TKM buffer fol-
lowed by recentrifugation before final resuspension
in 300 ml of TKM buffer. Ribosome concentration
was determined by measuring the OD of the sus-260
pension.
2.6. Mutagenesis
ra-Sarcin DNA in M was mutagenised using the13
T7-GENe in vitro mutagenesis kit United States
.Biochemicals according to the manufacturers in-
structions. Mutagenesis was confirmed by DNA se-
quencing using the dideoxy chain termination method.
2.7. Other toxins
Native ricin was purchased from Inland Laborato-
 .ries Austin, TX, USA and recombinant RTA, ex-
pressed in and purified from E. coli, was kindly
donated by Zeneca Pharmaceuticals Alderley Park,
.Cheshire, UK .
 .Fig. 1. Purification of ra-sarcin. a The 70% ammonium sulfate
supernatant from homogenates of E. coli expressing a-sarcin
was dialysed against 100 mM Tris.HCl, pH 9.0, 10 mM EDTA,
and then loaded onto a CM-Sepharose column. After washing to
remove unbound protein, ra-sarcin was eluted by a linear NaCl
 .gradient 0 to 750 mM in the above buffer. Aliquots from
selected fractions were analysed by SDS-PAGE and protein
bands were visualised by silver staining. Lane 1, molecular
weight markers; lanes 2 to 6, wash fractions that did not bind to
the column; lanes 7 to 11, fractions across the protein peak eluted
 .  .with NaCl; lane 12, native a-sarcin. b as a , but the gel was
blotted onto nitrocellulose and a-sarcin was visualised using
rabbit anti-a-sarcin serum.
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2.8. Other methods
DNA manipulations, SDS-polyacrylamide gel elec-
trophoresis and Western blotting were carried out by
standard published procedures. Antibodies against na-
tive a-sarcin were raised in rabbits.
3. Results
3.1. a-Sarcin production
 .Recombinant a-sarcin ra-sarcin produced in Es-
cherichia coli was used throughout this study. We
used an expression vector in which the chemically
synthesised a-sarcin gene was preceeded by an in
frame sequence encoding the N-terminal signal pep-
tide of the OmpA2 protein, a major outer membrane
protein of E. coli pIN.ompA2.preAS, which has
w x.been described earlier 20 . When this expression
vector was used initially, only very low levels of
w xa-sarcin production were seen 20 . Under the experi-
mental conditions used in the present work, IPTG-in-
duced expression in E. coli TG2 cells resulted in a
high level of a-sarcin production, and SDS-PAGE of
the total proteins present in homogenates from such
cells revealed the presence of a prominent band of
M ;17 kDa that was not present amongst the pro-r
teins from cells transformed with vector alone data
.not shown . The homogenate was brought to 70%
Fig. 2. Differential reduction of the disulfide bonds in ra-sarcin.
R a-sarcin was subjected to SDS-PAGE in sample buffer contain-
 .  . ing no dithiothreitol lane 1 or 0.1 mM lane 2 , 0.5 mM lane
.  .  .  .3 , 1 mM lane 4 , 5 mM lane 5 , or 50 mM lane 6 dithio-
threitol.
Fig. 3. RNase activity of ra-sarcin. Various concentrations of
native or ra-sarcin were incubated with rabbit reticulocyte ribo-
somes. The rRNA was then extracted and 3 mg of RNA was
resolved by agarose gel electrophoresis and visualised by staining
with ethidium bromide. The fragment diagnostic of specific RNA
cleavage in the a-sarcin loop is indicated by the arrow. Lane 1,
untreated ribosomes; lanes 2 to 4, ribosomes treated with 1
ngrml, 100 pgrml or 10 pgrml respectively of native a-sarcin;
lanes 5 to 7, ribosomes treated with 1 ngrml, 100 pgrml or 10
pgrml of ra-sarcin.
Fig. 4. Inhibition of in vitro protein synthesis by various concen-
 .  .  .trations of ra-sarcin v , native a-sarcin ^ or RTA I .
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saturation with ammonium sulfate which precipitated
the bulk of the endogenous E. coli proteins but not
the 17 kDa product. The 17 kDa product was purified
to homogeneity in a single step by passing the dial-
ysed supernatant through a 1.6=40 cm column con-
taining a CM Sepharose matrix. The endogenous E.
coli proteins did not bind to the column Fig. 1a,
.lanes 2 to 6 , and the bound 17 kDa protein was
eluted using a salt gradient as a single peak around
 .0.15 M NaCl Fig. 1a, lanes 7 to 11 . This protein
was identified as a-sarcin, having an identical elec-
trophoretic mobility to that of purified native a-sarcin
and reacting specifically with rabbit antibodies raised
 .against native a-sarcin Fig. 1b . A typical yield of
purified ra-sarcin produced by this method was 5
mgrl of bacterial culture.
3.2. Characterisation of ra-sarcin
Native a-sarcin contains two intramolecular disul-
fide bonds, linking cysteines residues at position 6
w xand 148, and 76 and 132 respectively 22 . R a-sarcin,
directed to the E. coli periplasmic space during its
synthesis, also contained two disulfide bonds. On
non-reducing SDS-PAGE gels, the disulfide cross-
linked a-sarcin displayed a higher electrophoretic
mobility than the dithiothreitol-reduced form, a frac-
tion with intermediate mobility confirming the pres-
 .ence of two disulfide bonds Fig. 2 . R a-sarcin was
soluble, being recovered quantitatively in the super-
natant when solutions were centrifuged at 100 000=g
for 1 h, and it remained soluble on storage data not
.shown .
R a-sarcin was catalytically active. This ribo-
nuclease cleaves 28S rRNA at a specific site close to
the 3X end of the molecule to generate a small RNA
fragment of ;390 ribonucleotides. The presence of
this fragment on denaturing formamide gels of total
RNA extracted from a-sarcin-treated ribosomes is
diagnostic of catalytic activity. As shown in Fig. 3,
ra-sarcin was biologically active, and a comparison
of the relative activities of different amounts of ra-
w35 xFig. 5. Cytotoxicity to HeLa cells. The ability of HeLa cells to incorporate S methionine into cellular protein was determined after
 .  .  .incubation for 16 h with various concentrations of ra-sarcin v , RTA I or ricin holotoxin B .
( )I.D. Syl˝ester et al.rBiochimica et Biophysica Acta 1358 1997 53–6058
sarcin with equivalent amounts of native a-sarcin
 .indicated that their activities were identical Fig. 3 .
This was confirmed by the demonstration that native
and ra-sarcin were indistinguishable in their ability
to inhibit in vitro protein synthesis in nuclease-treated
rabbit reticulocyte lysates programmed with brome
 . mosaic virus mRNA Fig. 4 , with IC the concen-50
tration of toxin required to give a 50% reduction in
. y10protein synthesis values of around 10 M. The in
vitro protein synthesis inhibition activity of a-sarcin
 .was essentially the same as that of RTA Fig. 4 .
3.3. The cytotoxicity of ra-sarcin
The cytotoxicity of ra-sarcin to cultured mam-
malian cells was determined by incubating HeLa
cells with various concentrations of toxin for 16 h
and susequently determining their ability to incorpo-
w35 xrate S methionine into cellular protein, expressed
as a percentage of the incorporation by control cells
not treated with toxin. The concentration of ra-sarcin
causing a 50% inhibition of protein synthesis was
5P10y6 M, exactly the same IC value as that50
 .determined for free RTA Fig. 5 . However, both
ra-sarcin and RTA were 6 orders of magnitude less
cytotoxic than intact ricin, which had an IC value50
y12  .of 5P10 M Fig. 5 .
Fig. 6. The RNasae activity of wild-type and mutant ra-sarcin.
Various concentrations of ra-sarcin or ra-sarcinE96A were incu-
bated with rabbit reticulocyte ribosomes, and rRNA was sepa-
rated and visualised as described in the legend to Fig. 3 Lane 1,
untreated ribosomes; lanes 2 to 7, ribosomes treated with 100
 .  .  .ngrml lane 2 , 50 ngrml lane 3 , 1 ngrml lane 4 , 100 pgrml
 .  .  .lane 5 , 10 pgrml lane 6 and 1 pgrml lane 7 of ra-sarcin;
lanes 8 to 13, as lanes 2 to 7 except that equivalent concentra-
tions of ra-sarcin E96A were assayed.
Fig. 7. Biological activity of ra-sarcinE96A. Inhibition of in vitro
 .  .protein synthesis a , and the cytotoxicity to HeLa cells b of
 .  .wild-type ra-sarcin v and ra-sarcinE96A ‘ .
3.4. Cytotoxicty of mutant ra-sarcin with reduced
RNAase acti˝ity
The Aspergillus ribotoxins share primary se-
w xquence homology with the RNAases U2 23,24 and
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w xT1 25 , and key residues present in the active site are
conserved. In the case of a-sarcin, the catalytic
residues are His50, Glu96, Arg121 and His137. We
constructed a point mutant in which Glu96 had been
 .converted to Ala ra-sarcinE96A . The mutant was
expressed in E. coli to the same level as wild-type
protein, and was purified to homogeneity by the same
procedure. Although the purified mutant retained
some RNAase activity, it was significantly less active
 .than wild-type ra-sarcin Fig. 6 . When ra-sarcin and
ra-sarcinE96A were compared in terms of their abil-
ity to inhibit in vitro protein synthesis, ra-sarcinE96A
was about 80-fold less active under the assay condi-
 .tions used Fig. 7a . The cytotoxicity of ra-
sarcinE96A to HeLa cells was also approximately
 .80-fold less than that of ra-sarcin Fig. 7b .
4. Discussion
It has been recognised for some time that a-sarcin
is cytotoxic to mammalian cells by causing the inhi-
w xbition of cellular protein synthesis 10 . Since a-sarcin
acts by specific cleavage of 28S rRNA, and since the
ribosomes are in the cytosol, catalytically active a-
sarcin must enter this cellular compartment. a-Sarcin
w xinteracts with phospholipid vesicles 13,14 , and it
has been suggested that this interaction may permit
the protein to directly cross the plasma membrane to
w xgain access to its substrate 9 . RTA is also cytotoxic
to mammalian cells, and it catalytically modifies the
same 28S rRNA region targeted by a-sarcin. Like
a-sarcin, RTA can also interact with phospholipid
vesicles, but it does not enter cells by direct traversal
w xof the plasma membrane 26 . In the ricin holotoxin,
RTA is covalently linked via a single disulfide bond,
 . w xto a second polypeptide the B chain or RTB 5 .
RTB is a galactose- and N-acetylgalactosamine-
specific lectin which is responsible for ricin binding
to mammalian cells through its interaction with cell
surface galactosides. Some of the bound toxin is
taken into the cells by endocytosis and, after vesicu-
lar transport, RTA crosses an intracellular membrane
in order to reach its substrate. Surface binding is
essential for potent cytotoxicity, since preventing
binding by adding free sugar or by abrogating the
RTB galactose binding sites dramatically reduces
w xricin toxicity 27–29 . Free RTA is still cytotoxic,
however, since at high enough extracellular concen-
tration a proportion can enter the cell dissolved in the
w xfluid taken up by the normal endocytic activity 26 .
Here we have shown that ra-sarcin produced in E.
coli, indistinguishable in all aspects from native a-
sarcin, is cytotoxic to HeLa cells with an IC of50
5P10y6 M. This IC value is in close agreement50
with values reported earlier for a-sarcin against a
w xnumber of different tumour cell lines 9 . Since a-
sarcin may promote permeability changes in phos-
w xpholipid vesicles 14 , its toxicity to intact cells could
conceivably result from damage to the plasma mem-
brane rather than cleavage of 28S rRNA. This did not
seem to be the case, however, since cells incubated
with a-sarcin did not leak lactate dehydrogenase
suggesting that they had not been permeabilised to
w xmacromolecules 16 . In the present study we show
that a point mutation in an active site residue reduces
both the in vitro protein synthesis inhibition ability
and the cytotoxicity of ra-sarcin to a similar extent, a
correlation that strongly suggests that cytotoxicity is
a consequence of RNAase activity rather than a
generalised loss of cytosol resulting from damage to
the plasma membrane.
The ability of a-sarcin to inhibit in vitro protein
synthesis is essentially the same as that of free RTA.
Both toxins have equivalent toxic potency to HeLa
cells, but both are 106-fold less potent than intact
ricin. One possible explanation for a-sarcin and RTA
having the same cytotoxicity is that they have the
same ability to reach their ribosomal substrate be-
cause they enter cells by the same mechanism. RTA
is apparently unable to bind directly to surface com-
ponents and to use such components for receptor-
w xmediated endocytosis 19 . When the ability to bind
to the cell surface is restored to RTA by coupling it
to antibodies raised against cell surface antigens or to
a natural ligand for cell surface receptors, the RTA-
containing conjugates can have the same cytotoxicity
w xas intact ricin 30 . This suggests that in ricin the
crucial role of RTB in toxicity is cell surface binding,
and that it does not have a necessary role in RTA
translocation across a membrane. Free RTA is cyto-
toxic at high concentration, however, and its cyto-
toxic potency is equal to that of a-sarcin. We have
recently shown that free RTA follows the same intra-
cellular transport route as intact ricin indicating that
there is a single intracellular site from which RTA
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translocates into the cytosol, regardless of the mecha-
w xnism or the efficiency of cell entry 19 . Since a-
sarcin, in common with RTA, seems to be incapable
of directly traversing the plasma membrane, it may
reach the cytosol by the same route as ricin and RTA.
Alternatively a-sarcin might enter mammalian cells
using a different mechanism to RTA, possibly differ-
ing in the initial endocytic entry step or in intra-
cellular trafficking and the site of toxin translocation
into the cell cytosol. If this is the case, then the
relative efficiencies of the two routes are clearly very
similarsince a-sarcin and RTA exhibit equivalent
cytotoxic potencies.
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